• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Insmed Incorporated

    6/16/25 5:01:19 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INSM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001402051
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    INSMED Inc
    SEC File Number
    000-30739
    Address of Issuer
    700 US HIGHWAY 202/206
    BRIDGEWATER
    NEW JERSEY
    08807
    Phone
    908-977-9900
    Name of Person for Whose Account the Securities are To Be Sold
    Lewis William
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Merrill Lynch
    1800 K ST NW
    Suite 800
    Washington � DC � 20006
    13500913549587.0018213892306/16/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/16/2025Stock Plan ActivityIssuerCheckbox not checked12980506/16/2025n/a
    Common06/01/2025Stock Plan ActivityIssuerCheckbox not checked520406/01/2025n/a

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    William Lewis
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common06/03/20255472391248.00
    William Lewis TTEE
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common06/02/20256830486834.00
    William Lewis
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common05/20/2025210571423819.00
    William Lewis TTEE
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common05/20/20256830462314.00
    William Lewis
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common05/14/20253771247415.00
    William Lewis
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common05/13/2025174421168090.00
    William Lewis TTEE
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common05/01/20256830495448.00
    William Lewis TTEE
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common04/15/20256830478933.00
    William Lewis TTEE
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common04/01/20256830502352.00
    William Lewis
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common03/17/2025187501443628.00
    William Lewis TTEE
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common03/17/20256830525958.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/16/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    09/12/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    William Lewis

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $INSM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INSM

    DatePrice TargetRatingAnalyst
    8/20/2025Outperform
    William Blair
    8/13/2025$126.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$105.00Buy
    Jefferies
    2/25/2025$100.00Outperform
    RBC Capital Mkts
    4/23/2024$48.00Buy
    Truist
    2/15/2024$42.00Outperform
    Wolfe Research
    12/8/2023$55.00Overweight
    Wells Fargo
    11/20/2023$36.00Overweight
    JP Morgan
    More analyst ratings

    $INSM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Insmed Incorporated

    SCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)

    9/4/25 1:41:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Insmed Incorporated

    SCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)

    8/14/25 1:07:20 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Insmed Incorporated

    144 - INSMED Inc (0001104506) (Subject)

    8/12/25 4:37:13 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desjardins Clarissa bought $201,694 worth of shares (3,025 units at $66.68) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    5/22/25 5:20:35 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Strategy Officer Schaeffer Orlov S Nicole gifted 23,303 shares, decreasing direct ownership by 29% to 56,461 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    9/5/25 4:25:45 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Smith Michael Alexander exercised 12,780 shares at a strike of $30.46 and sold $3,492,378 worth of shares (24,272 units at $143.89), decreasing direct ownership by 17% to 54,902 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    9/4/25 5:26:29 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Flammer Martina M.D. exercised 186,648 shares at a strike of $23.40 and sold $26,941,272 worth of shares (186,648 units at $144.34) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    9/4/25 5:24:22 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Insmed

    William Blair initiated coverage of Insmed with a rating of Outperform

    8/20/25 8:56:07 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Insmed from Overweight to Equal-Weight and set a new price target of $126.00

    8/13/25 8:02:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Insmed with a new price target

    Jefferies initiated coverage of Insmed with a rating of Buy and set a new price target of $105.00

    5/13/25 9:43:52 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Sept. 5, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 115 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commen

    9/5/25 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution

    NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Bloomberg Indices announced the following changes to the Bloomberg 500 (B500) Index effective prior to the open of trading on Thursday, September 11, to coincide with the semi-annual reconstitution of the index. The B500 contains the 500 most highly capitalized US companies weighted by float market cap, reflecting a market capitalization of $58.19 trillion. Affirm Holdings, Inc. (AFRM), Astera Labs, Inc. (ALAB), The Carlyle Group, Inc. (CG), CyberArk Software, Ltd. (CYBR), EMCOR Group, Inc. (EME), Comfort Systems USA, Inc. (FIX), Insmed,

    8/27/25 4:32:00 PM ET
    $AFRM
    $AKAM
    $ALAB
    Finance: Consumer Services
    Finance
    Real Estate
    Semiconductors

    Insmed To Present at September Investor Conferences

    BRIDGEWATER, N.J., Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Wells Fargo 2025 Healthcare Conference in Boston, on Friday, September 5, 2025, at 8:00 a.m. ET.Morgan Stanely 23rd Annual Global Healthcare Conference in New York, on Tuesday, September 9, 2025, at 4:50 p.m. ET.These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be

    8/21/25 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

    —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics. "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year

    10/24/24 4:05:00 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Names Drayton Wise Chief Commercial Officer

    BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti

    5/23/22 8:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Financials

    Live finance-specific insights

    View All

    FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

    — Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed to Host Investor Conference Call Today at 12:00 PM ET  — BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious

    8/12/25 11:34:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

    BRIDGEWATER, N.J., July 24, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2025 financial results on Thursday, August 7, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 7, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing acces

    7/24/25 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

    –The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001) 35.5 Meter Placebo-Adjusted Improvement in Six-Minute Walk Distance for the Secondary Efficacy Endpoint (p=0.003) 60% Placebo-Adjusted Reduction from Baseline in NT-proBNP Concentrations for the Secondary Efficacy Endpoint (p<0.001) Results Were Assessed Approximately 24 Hours After Administration, Demonstrating Sustained Benefit Throughout the 24-Hour Dosing Period–TPIP Was Well Tolerated in the Study, with 75% of Patients Titrating to the Highest Dose– –Insmed to Immediately Engage with FDA t

    6/10/25 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Insmed Incorporated

    SC 13G - INSMED Inc (0001104506) (Subject)

    9/3/24 5:22:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Insmed Incorporated (Amendment)

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    2/16/24 5:43:57 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care